Cytori Therapeutics (CYTX) Misses Q3 EPS by 5c

Cytori Therapeutics (NASDAQ: CYTX) reported Q3 EPS of ($0.12), $0.05 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $3.16 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
• Morgan Stanley Starts Amplifon SpA (AMP:IM) (AMFPF) at Overweight